Weave Bio
PrivateLast Round
Series A
Oct 16, 2025
Total Funding Raised
$36M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Weave Bio operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series A round in October 2025.
Weave Bio is a digital health company that provides an AI-native regulatory automation platform to streamline document preparation and lifecycle management for pharmaceutical and biotech companies.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Data Integration, Workflow Automation, RegTech, Biotechnology
Business Model
B2B
Customer Profile
Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Weave Bio Comparables
Compare Weave Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hill Research | 83% | |
| Artos | 83% | |
| AlphaLife Sciences | 81% |
For institutional investors. Book with your work email.
Weave Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 16, 2025 | ||||
| Seed | May 30, 2024 | ||||
| Pre Seed | Aug 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Weave Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Magnetic Ventures | Series A, Pre Seed, Seed |
| Innovation Endeavors | Series A, Pre Seed, Seed |
| Magnetic Ventures | Series A, Seed |
| Character Capital | Series A |
| U.S. Venture Partners | Series A |
| TMV | Series A |
| Serrado Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 4, 2026
Messaging infrastructure processes hundreds of millions of messages.
- Apr 4, 2026
Platform processes billions in annual payment volume.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- integrates_withSep 2, 2026
Weave aims to integrate its AI-native regulatory automation platform with Takeda Pharmaceutical Co.'s regulatory experience across 14 ongoing drug development programmes to streamline regulatory workflows.
For institutional investors. Book with your work email.
Weave Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Weave Bio's valuation, stock price, and market status.
Is Weave Bio a public or private company?
Weave Bio is a private company.
What is the current stock price of Weave Bio?
Weave Bio is a private company, so its shares have no public market price. Caplight tracks Weave Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Weave Bio worth (valuation)?
Valuation information for Weave Bio is not publicly available.
Can I buy Weave Bio stock?
Weave Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Weave Bio's last funding round?
Weave Bio's most recent funding round was Series A on October 16, 2025.
Who are the main investors in Weave Bio?
Key investors in Weave Bio include Magnetic Ventures, Innovation Endeavors, Magnetic Ventures, U.S. Venture Partners.
Will Weave Bio IPO soon?
No public IPO plans have been announced for Weave Bio.
How can I track Weave Bio secondary market activity?
Caplight tracks bids, offers, and trades in Weave Bio's shares on secondary markets.